128 related articles for article (PubMed ID: 9142433)
1. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
Kato K
Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
[TBL] [Abstract][Full Text] [Related]
3. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
[TBL] [Abstract][Full Text] [Related]
4. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
[TBL] [Abstract][Full Text] [Related]
5. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
[TBL] [Abstract][Full Text] [Related]
7. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
Lubsen J; Just H; Hjalmarsson AC; La Framboise D; Remme WJ; Heinrich-Nols J; Dumont JM; Seed P
Heart; 1996 Sep; 76(3):223-31. PubMed ID: 8868980
[TBL] [Abstract][Full Text] [Related]
8. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study.
Erlemeier HH; Kupper W; Bleifeld W
Eur Heart J; 1991 Aug; 12(8):889-99. PubMed ID: 1915427
[TBL] [Abstract][Full Text] [Related]
10. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Fitton A; Brogden RN
Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
Sasayama S; Asanoi H; Kihara Y; Yokawa S; Terada Y; Yoshida S; Ejiri M; Horikoshi I
Heart Vessels; 1994; 9(3):113-20. PubMed ID: 8056717
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
Hagemeijer F; Brand HJ; Roth W
J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
[TBL] [Abstract][Full Text] [Related]
14. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
Kubo SH
Cardiology; 1997; 88 Suppl 2():21-7. PubMed ID: 9142432
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
[TBL] [Abstract][Full Text] [Related]
16. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
17. Use of pimobendan in 170 cats (2006-2010).
Macgregor JM; Rush JE; Laste NJ; Malakoff RL; Cunningham SM; Aronow N; Hall DJ; Williams J; Price LL
J Vet Cardiol; 2011 Dec; 13(4):251-60. PubMed ID: 22030289
[TBL] [Abstract][Full Text] [Related]
18. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
Permanetter B; Sebening H; Busch U; Lutilsky L
Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013
[TBL] [Abstract][Full Text] [Related]
19. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Hauf GF; Grom E; Jähnchen E; Roskamm H
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
[TBL] [Abstract][Full Text] [Related]
20. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
